Palatin Technologies (PTN) Current Assets (2011 - 2026)
Palatin Technologies' (PTN) quarterly Current Assets came in at $12.8 million in Q1 2026, up 295.43% on a YoY basis from $3.2 million in Q1 2025, and down 26.81% quarter-over-quarter from $17.5 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Current Assets (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Current Assets for 15 consecutive years, with $12.8 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Current Assets rose 295.43% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (up 295.43% YoY), and the FY2025 full-year result was $2.9 million, down 70.12% from the prior year.
- Current Assets eased to $12.8 million in Q1 2026 per PTN's latest filing, from $17.5 million in the prior quarter.
- Across five years, Current Assets topped out at $42.2 million in Q1 2022 and bottomed at $2.6 million in Q3 2024.
- Historically, Current Assets has averaged $15.7 million across 5 years, with a median of $12.2 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Current Assets tumbled 73.36% in 2024, then surged 375.99% in 2025.
- Over 5 years, Current Assets stood at $30.6 million in 2022, then plunged by 59.92% to $12.2 million in 2023, then plunged by 70.03% to $3.7 million in 2024, then soared by 375.99% to $17.5 million in 2025, then decreased by 26.81% to $12.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $12.8 million, $17.5 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.96 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 13.95 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 12.54 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 18.45 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 8.07 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.82 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 7.31 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 4.74 Bn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 12.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 12.79 Mn |
| Dec 31, 2025 | 17.47 Mn |
| Sep 30, 2025 | 8.37 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Mar 31, 2025 | 3.23 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 9.77 Mn |
| Mar 31, 2024 | 10.27 Mn |
| Dec 31, 2023 | 12.25 Mn |
| Sep 30, 2023 | 9.81 Mn |
| Jun 30, 2023 | 16.32 Mn |
| Mar 31, 2023 | 24.24 Mn |
| Dec 31, 2022 | 30.55 Mn |
| Sep 30, 2022 | 26.18 Mn |
| Jun 30, 2022 | 34.60 Mn |
| Mar 31, 2022 | 42.25 Mn |
| Dec 31, 2021 | 51.37 Mn |
| Sep 30, 2021 | 58.39 Mn |
| Jun 30, 2021 | 65.91 Mn |